Thrombin inhibition profiles in healthy individuals and thrombophilic patients
- 1 January 2012
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 107 (05), 848-853
- https://doi.org/10.1160/th11-10-0719
Abstract
Inhibition of thrombin by endogenous inhibitors plays a central role in the spatiotemporal control of clot formation. A failure to adequately inactivate thrombin such as in antithrombin deficiency generates a strong prothrombotic phenotype. To study if and to what extent delayed thrombin inactivation rates beyond antithrombin deficiency contribute to the prothrombotic phenotype we measured thrombin inhibition profiles in plasma samples obtained from 16 healthy individuals and 39 thrombophilic patients, including 17 patients diagnosed positive for anti-prothrombin/phospholipid antibodies. To test thrombin inhibition, thrombin was added to plasma, and endogenous thrombin inhibition stopped by addition of the reversible thrombin inhibitor argatroban. Subsequently, the amount of argatroban-complexed thrombin was measured using an oligonucleotide-based enzyme capture assay. In normal human plasma thrombin at concentrations up to 4 ng/ml (109 pM) became inactivated with an average half-life time of 56.4 ± 4.7 seconds (s). In antithrombin-deficient plasma the thrombin half-life was prolonged to 168.2 ± 14.9 s. Among the thrombophilic patients, only one with mild antithrombin deficiency showed impaired thrombin inactivation rates, whereas all other patients including the antiphospholipid positive patients showed thrombin inhibiting capacities within the normal range. We conclude that thrombin added to normal human plasma at subthreshold levels of ∼100 pM or below becomes inactivated with a half-life time below 1 minute. Antiphospholipid antibodies do not prolong thrombin half-life times, making it unlikely that delayed thrombin inactivation contributes to the thrombotic phenotype of the antiphospholipid syndrome. In contrast, plasma levels of antithrombin falling below 80% of normal markedly prolong the thrombin half-life. Both authors contributed equally to the study.This publication has 13 references indexed in Scilit:
- Thrombin Generation in Hemorrhage Control and Vascular OcclusionCirculation, 2011
- Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasisArthritis & Rheumatism, 2011
- Profiling of Active Thrombin in Human Blood by Supramolecular ComplexesAngewandte Chemie, 2011
- Blood Coagulation: Hemostasis and Thrombin RegulationAnesthesia & Analgesia, 2009
- Inherited antithrombin deficiency: a reviewHaemophilia, 2008
- Thrombin generation: a comparison of assays using platelet‐poor and ‐rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolismBritish Journal of Haematology, 2007
- Serpins in thrombosis, hemostasis and fibrinolysisJournal of Thrombosis and Haemostasis, 2007
- The central role of thrombin in hemostasisJournal of Thrombosis and Haemostasis, 2007
- Thrombin generation, a function test of the haemostaticthrombotic systemThrombosis and Haemostasis, 2006
- Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with antithrombin antibody from a patient with antiphospholipid syndromeThrombosis and Haemostasis, 2005